Artivion (AORT) Plunge 5.8% on Q4 Revenue Miss Despite Positive Outlook

Artivion (NYSE:AORT) fell 5.8% in trading on February 13, 2026, after reporting mixed fourth-quarter 2025 results. Revenue of $116 million reflects a 19.2% year-over-year increase but missed analyst expectations. Non-GAAP profit of $0.17 per share matched estimates, while the midpoint of full-year 2026 revenue guidance of $443 million, 1% above consensus, and EBITDA guidance, which exceeded expectations, were positive. The top-line miss outweighed the guidance, sending shares down despite the stock’s low volatility and a 21% discount to its 52-week high of $47.63. Context: In Q2 2025, Artivion beat earnings and raised guidance, with revenue up 15.3% to $113 million and free cash flow margin expanding to 10.4%. The stock is down 15.3% YTD but remains a buy opportunity for investors considering high-quality, cash-flow improving medical device companies.